SE9604731D0 - A component of intercellular junctions in the endothelium - Google Patents

A component of intercellular junctions in the endothelium

Info

Publication number
SE9604731D0
SE9604731D0 SE9604731A SE9604731A SE9604731D0 SE 9604731 D0 SE9604731 D0 SE 9604731D0 SE 9604731 A SE9604731 A SE 9604731A SE 9604731 A SE9604731 A SE 9604731A SE 9604731 D0 SE9604731 D0 SE 9604731D0
Authority
SE
Sweden
Prior art keywords
endothelium
component
intercellular junctions
cadherin molecule
antibodies
Prior art date
Application number
SE9604731A
Other languages
Swedish (sv)
Inventor
Elisabetta Dejana
Paola Telo
Original Assignee
Tamas Bartfai Konsulting Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tamas Bartfai Konsulting Ab filed Critical Tamas Bartfai Konsulting Ab
Priority to SE9604731A priority Critical patent/SE9604731D0/en
Publication of SE9604731D0 publication Critical patent/SE9604731D0/en
Priority to JP52665598A priority patent/JP2002512505A/en
Priority to EP97948160A priority patent/EP0889900A1/en
Priority to CA002245956A priority patent/CA2245956A1/en
Priority to PCT/US1997/020006 priority patent/WO1998025946A1/en
Priority to AU54283/98A priority patent/AU5428398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A new VE-cadherin molecule is provided. Monoclonal antibodies that specifically bind to and neutralize an extracellular domain of a VE-cadherin molecule are provided. In vitro and in vivo methods of using these antibodies are also provided.
SE9604731A 1996-12-12 1996-12-20 A component of intercellular junctions in the endothelium SE9604731D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9604731A SE9604731D0 (en) 1996-12-20 1996-12-20 A component of intercellular junctions in the endothelium
JP52665598A JP2002512505A (en) 1996-12-20 1997-11-05 Monoclonal antibodies specific for endothelial cell cadherins and their uses
EP97948160A EP0889900A1 (en) 1996-12-12 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
CA002245956A CA2245956A1 (en) 1996-12-20 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
PCT/US1997/020006 WO1998025946A1 (en) 1996-12-12 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
AU54283/98A AU5428398A (en) 1996-12-12 1997-11-05 Monoclonal antibodies specific to endothelial cell cadherins and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604731A SE9604731D0 (en) 1996-12-20 1996-12-20 A component of intercellular junctions in the endothelium

Publications (1)

Publication Number Publication Date
SE9604731D0 true SE9604731D0 (en) 1996-12-20

Family

ID=20405090

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604731A SE9604731D0 (en) 1996-12-12 1996-12-20 A component of intercellular junctions in the endothelium

Country Status (6)

Country Link
EP (1) EP0889900A1 (en)
JP (1) JP2002512505A (en)
AU (1) AU5428398A (en)
CA (1) CA2245956A1 (en)
SE (1) SE9604731D0 (en)
WO (1) WO1998025946A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
CN101053573A (en) * 2000-01-19 2007-10-17 帕卡什·S·吉尔 Compositions and methods based on VEGF antisense oligonucleotides
AU2001233702A1 (en) * 2000-01-25 2001-08-07 Novartis Ag Disease-associated gene
US20020081599A1 (en) * 2000-04-18 2002-06-27 Curtis Rory A. J. 57809 and 57798, novel human cadherin molecules and uses therefor
GB0010630D0 (en) 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
JP2005501528A (en) * 2001-06-05 2005-01-20 エクセリクシス・インコーポレイテッド GFATs as p53 pathway modifiers and methods of use
AU2003229627A1 (en) * 2002-04-08 2003-10-20 Max-Planck-Gesellschaft Zur Ve-ptp as regulator of ve-cadherin mediated processes or disorders
AU2003298475A1 (en) 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US20040167076A1 (en) 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
WO2008039525A2 (en) * 2006-09-27 2008-04-03 Adherex Technologies, Inc. Cadherin antagonists in combination with anticancer agents for use in cancer treatment
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
EP2694969B1 (en) 2011-04-08 2015-07-01 Institut National de la Sante et de la Recherche Medicale (INSERM) Anti-ve-cadherin autoantibodies as a biomarker of vascular alterations associated with disorders
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
EP4337256A1 (en) * 2021-07-19 2024-03-20 Eisai R&D Management Co., Ltd. Biomarkers for a therapy comprising an angiogenesis inhibitor

Also Published As

Publication number Publication date
CA2245956A1 (en) 1998-06-18
WO1998025946A1 (en) 1998-06-18
JP2002512505A (en) 2002-04-23
EP0889900A1 (en) 1999-01-13
AU5428398A (en) 1998-07-03

Similar Documents

Publication Publication Date Title
SE9604731D0 (en) A component of intercellular junctions in the endothelium
EA199801043A1 (en) ANTIBODIES AGAINST ED-B DOMAIN IN FIBRONECTIN, THEIR DESIGN AND USE
YU28503A (en) Humanized anti-lt-betha-r antibodies
EP0741748A4 (en) Monoclonal antibodies specific to vegf receptors and uses thereof
DE60334364D1 (en) TREATMENT PROCEDURE USING ANTI-CD22 ANTIBODIES
DK0724456T3 (en) CD40 antibodies
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
TR199801390T2 (en) Anticoagulants to be used in the treatment of thrombosis
DK0670735T3 (en) Peripheral Hematopoietic Stem Cells.
NO993739L (en) Diesel additive to improve cetane, lubricity and stability
CY2008003I1 (en) HUMAN MONOCLONAL ANTIBODIES TO EPITERNAL GROWTH FACTOR RECEPTOR
ES2110230T3 (en) RAPAMICINE TEST.
ATE220795T1 (en) RECOVERY OF TAXANS FROM CONIFIERS
DE60039416D1 (en) USE OF VASCULAR ENDOTHELIAL GROWTH FACTOR 2 (VEGF-2)
ATE161582T1 (en) MONOCLONAL ANTIBODIES OF THE MOUSE
HUP0101151A3 (en) Monoclonal antibody anti alphav-integrin and its use to inhibit alphavbetha6-integrin attachment to fibnronectin
EA200400930A1 (en) BLOCKING MONOCLONAL ANTIBODY TO VLA-1 OR ITS USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE60042941D1 (en) USE OF ANTI-CD3 MONOCLONAL ANTIBODIES AND IL-5 FOR THE TREATMENT OF AUTOIMMUNE DISEASES
SE0002835D0 (en) Method and kit for production of monoclonal antibodies
ATE165594T1 (en) TRIARYLETHYLENE DERIVATIVES FOR THERAPEUTIC USE
DE69324038D1 (en) ANISOTROPE COMPOSITE FOR HYPER FREQUENCIES
ECSP972005A (en) ANTICOAGULANT AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS
BR9709080A (en) Human anti-MP52 monoclonal antibody
FI956041A0 (en) Compositions and diagnostic methods using monoclonal antibodies to CD44V6
ITMI960789V0 (en) PHONE HOLDER WITH TONGUE OF ATTACHMENT TO THE BELT OF THE TROUSERS CONSTITUTED BY THE SAME FLAP THAT BY PASSING THROUGH OPPORTUNITY